March 29, 2024 16:11 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
PM Modi to kickstart BJP's Lok Sabha poll campaign from Meerut | Kangana Ranaut in Mandi: 'Don't think I am a heroine, consider me as your sister and daughter' | Mayawati, Akhilesh Yadav demand high-level probe into Mukhtar Ansari's death | PM Modi has mastered art of manipulating democracy, hurting Constitution: Mallikarjun Kharge | Mafia-turned-politician Mukhtar Ansari dies of cardiac arrest at 63
WHO discontinues trials of hydroxychloroquine, lopinavir/ritonavir in COVID-19 treatment

WHO discontinues trials of hydroxychloroquine, lopinavir/ritonavir in COVID-19 treatment

India Blooms News Service | @indiablooms | 05 Jul 2020, 03:05 am

Geneva/IBNS: The World Health Organisation (WHO) has informed that it is discontinuing the use of hydroxychloroquine and lopinavir/ritonavir arms in COVID-19 treatment for hospitalised patients as a part of its Solidarity Trial, stating the drugs had little effect on reducing the mortality rate.

The Solidarity Trial was established by WHO to find an effective treatment for hospitalised patients infected with the deadly virus.

In a statement on Saturday, the WHO said: "The International Steering Committee formulated the recommendation in light of the evidence for hydroxychloroquine vs standard-of-care and for lopinavir/ritonavir vs standard-of-care from the Solidarity trial interim results, and from a review of the evidence from all trials presented at the 1-2 July WHO Summit on COVID-19 research and innovation."

These interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care, WHO stated.

Solidarity trial investigators will interrupt the trials with immediate effect.

"For each of the drugs, the interim results do not provide solid evidence of increased mortality. There were, however, some associated safety signals in the clinical laboratory findings of the add-on Discovery trial, a participant in the Solidarity trial. These will also be reported in the peer-reviewed publication," the statement said.

"This decision applies only to the conduct of the Solidarity trial in hospitalised patients and does not affect the possible evaluation in other studies of hydroxychloroquine or lopinavir/ritonavir in non-hospitalized patients or as pre- or post-exposure prophylaxis for COVID-19," WHO clarified.

The interim Solidarity results are now being readied for peer-reviewed publication.

 


 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.